-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Coronavirus disease
Coronavirus diseaseCase reports and retrospective observational cohort studies suggest that treatment with tocilizumab (tocilizumab), an anti-interleukin-6 receptor monoclonal antibody, can improve the prognosis of patients with severe new coronary pneumonia.
In this phase 3 trial, researchers randomly divided hospitalized patients with severe new coronary pneumonia into two groups at 2:1, and received a single intravenous infusion of tocilizumab (8 mg/kg) or placebo.
A total of 452 patients were randomized, of which 438 (294 in the tocilizumab group and 144 in the placebo group) entered the first and second analyses.
On the 28th day, the median values of the clinical status of the tocilizumab group and the placebo group were 1.
In short, in this randomized trial of patients with severe new coronary pneumonia, treatment with tocilizumab did not significantly improve the clinical condition of patients at 28 days or reduce mortality.
Treatment with tocilizumab did not significantly improve the patient's clinical condition at 28 days or reduce mortality.
Original source:
Rosas Ivan O, Brou Norbert, Waters Michael et al.
org/10.
1056/NEJMoa2028700">Tocilizumab in Hospitalized Patients with Severe Covid- 19 Pneumonia in this message